Skip to main content
Toggle navigation
Login
Search
Home
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Home
Browse by Poster Presenter
Browse by Poster Presenter
Type here to filter the list
All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
M
Mühlenberg, Thomas
Department of Medical Oncology, Sarcoma Center, West German Cancer Center, University Duisburg-Essen, Medical School, Essen, Germany
(
P 108
)
NILOTINIB REVISITED: SALVAGE USE IN PATIENTS WITH SEVERE IMATINIB-TOXICITY
Thomas Mühlenberg
Favorite
Maale, Gerhard
Dallas Fort Worth Sarcoma Group
(
P 095
)
A COLLABORATIVE MULTIDISCIPLINARY APPROACH MAY LEAD TO ENHANCED CLINICAL OUTCOMES AND QUALITY OF CARE FOR PATIENTS WITH DIFFUSE TGCT
Gerhard Maale
Favorite
(
P 236
)
EVALUATION OF HISTOLOGIC CHANGES OF TENOSYNOVIAL GIANT CELL TUMORS FOLLOWING TREATMENT WITH PEXIDARTINIB
Gerhard Maale
Favorite
(
P 248
)
RESULTS OF A NEOADJUVANT REGIMEN USING A FIXED DOSE OF ADRIAMYCIN AS AN ELECTRON AFFINIC AGENT WITH 27GY FOLLOWED BY WIDE LOCAL RESECTION OF SOFT TISSUE SARCOMAS
Gerhard Maale
Favorite
(
P 297
)
PREOPERATIVE EMBOLIZATION TO REDUCE THE RISK OF HEMORRHAGE FOR HEMANGIOPERICYTOMA RESECTION
Gerhard Maale
Favorite
MacAlpine, Elle
School of Medicine, Duke University
(
P 171
)
CANINE-DERIVED OSTEOSARCOMA ORGANOIDS MODEL TUMOR HETEROGENEITY AND CHEMOTHERAPY RESISTANCE
Elle MacAlpine
Favorite
Mack, Jennifer W
Boston Children's/DFCI
(
P 237
)
EVOLUTIONARILY INSPIRED THERAPY FOR NEWLY DIAGNOSED, METASTATIC, FUSION POSITIVE RHABDOMYOSARCOMA, TRIAL IN PROGRES, NCT04388839, A REPORT FROM THE NATIONAL PEDIATRIC CANCER FOUNDATION
Jennifer W Mack
Favorite
Mack, Lloyd
University of Calgary
(
P 205
)
PREOPERATIVE CHEMORADIATION (MODIFIED EILBER PROTOCOL) VERSUS NEOADJUVANT/ ADJUVANT RADIOTHERAPY FOR SOFT TISSUE EXTREMITY SARCOMAS: A POPULATION BASED ANALYSIS IN ALBERTA
Lloyd Mack
Favorite
Mack, Tanner
The University of Ottawa / The Ottawa Hospital
(
P 112
)
PREVALENCE AND PROGNOSTIC VALUE OF TARGETABLE RECEPTORS IN EXTRA-UTERINE LEIOMYOSARCOMA
Tanner Mack
Favorite
MacLean, Joseph
Cincinnati Children's Hospital Medical Center
(
P 118
)
SOMATOSTATIN RECEPTOR TYPE 2 EXPRESSION IN SARCOMA
Joseph MacLean
Favorite
Macy, Margaret
Children’s Hospital of Colorado
(
P 239
)
FGFR IS A RELEVANT MOLECULAR TARGET IN PEDIATRIC AND AYA SARCOMAS
Margaret Macy
Favorite
Maejima, Aiko
Department of Medical Oncology, National Cancer Center Hospital
(
P 147
)
ANALYSIS OF INFLAMMATORY BIOMARKERS AS PREDICTORS OF TREATMENT EFFICACY IN SOFT TISSUE SARCOMA TREATED WITH TRABECTEDIN
Aiko Maejima
Favorite
Maese, Luke
Primary Children’s Hospital
(
P 239
)
FGFR IS A RELEVANT MOLECULAR TARGET IN PEDIATRIC AND AYA SARCOMAS
Luke Maese
Favorite
Maestro, Roberta
Centro di Riferimento Oncologico di Aviano (CRO), IRCCS
(
P 170
)
ANTITUMOR ACTIVITY OF TAZEMETOSTAT AND DOXORUBICIN COMBINATION ON PATIENT-DERIVED PRECLINICAL MODELS OF EPITHELIOID SARCOMA
Roberta Maestro
Favorite
Magagnoli, Giovanna
Deapartment of Pathology, IRCCS, Istituto Ortopedico Rizzoli, Bologna, Italy
(
P 245
)
MUTATIONAL STATUS OF CHONDROSARCOMA BASED ON TARGETED NEXT-GENERATION SEQUENCING ANALYSIS
Giovanna Magagnoli
Favorite
Magnotta, Vincent
University of Iowa Hospitals & Clinics
(
P 160
)
NEOADJUVANT PHARMACOLOGICAL ASCORBATE WITH CONCURRENT RADIATION IN LOCALLY ADVANCED SOFT-TISSUE SARCOMA OF EXTREMITY/TRUNK AND RETROPERITONEUM
Vincent Magnotta
Favorite
Magnusson, Linda
Lund University
(
P 014
)
A PLETHORA OF DISEASE-ASSOCIATED ALTERATIONS IN OSTEOSARCOMA
Linda Magnusson
Favorite
(
P 024
)
GENETIC REARRANGEMENTS IN 12Q-AMPLIFIED OSTEOSARCOMA RESULT IN ECTOPIC GENE EXPRESSION THROUGH TRANSPOSITION OF REGULATORY ELEMENTS AND SELECTIVE AMPLIFICATION
Linda Magnusson
Favorite
(
P 242
)
LIPOSARCOMAS WITH 12Q AMPLIFICATION - CAN GENETIC CHANGES DISCLOSE THE DEVELOPMENT AND ORIGIN OF RING CHROMOSOMES?
Linda Magnusson
Favorite
Mahajan, Anita
Mayo Clinic
(
P 020
)
DEFINITIVE RADIATION THERAPY FOR EWING SARCOMA: TREATMENT AND TOXICITY OUTCOMES IN PATIENTS TREATED WITH DOSE ESCALATION APPROACHES
Anita Mahajan
Favorite
(
P 201
)
LOCAL CONTROL AND SURVIVAL OUTCOMES IN PEDIATRIC NON-RHABDOMYOSARCOMA SOFT TISSUE SARCOMA: THE MAYO CLINIC EXPERIENCE
Anita Mahajan
Favorite
Maki, Robert
Abramson Cancer Center
(
P 041
)
UPDATED EFFICACY AND SAFETY OF THE TETRAVALENT DEATH RECEPTOR 5 AGONIST INBRX-109 IN PATIENTS WITH CHONDROSARCOMA: DATA FROM THE PHASE 1 EXPANSION COHORTS
Robert Maki
Favorite
(
P 314
)
A PHASE II/III, RANDOMIZED, OPEN LABEL, MULTICENTER STUDY OF THE MDM2–P53 ANTAGONIST BI 907828 VS DOXORUBICIN IN THE FIRST-LINE TREATMENT OF PATIENTS WITH DEDIFFERENTIATED LIPOSARCOMA: BRIGHTLINE-1
Robert Maki
Favorite
Makker, Vicky
Memorial Sloan Kettering Cancer Center
(
P 134
)
PHASE II STUDY OF RUCAPARIB AND NIVOLUMAB IN PATIENTS WITH LEIOMYOSARCOMA
Vicky Makker
Favorite
Malko, Rada
Indiana University
(
P 192
)
TARGETING PI3K/MTOR MITIGATES RESISTANCE TO CDK4/6 INHIBITION IN RB-PROFICIENT PEDIATRIC AND AYA OSTEOSARCOMAS
Rada Malko
Favorite
Malvar, Jemily
Children's Hospital Los Angeles
(
P 037
)
SURVIVAL OUTCOMES AND POST-SURGICAL MORBIDITY BASED ON SURGICAL APPROACH TO PULMONARY METASTASECTOMY IN PATIENTS WITH OSTEOSARCOMA
Jemily Malvar
Favorite
(
P 045
)
DETECTION OF CELL-FREE TUMOR DNA IN PATIENTS WITH NEWLY DIAGNOSED PEDIATRIC BONE AND SOFT TISSUE SARCOMAS
Jemily Malvar
Favorite
Mandel, Anna
University of Toronto
(
P 190
)
SELECTIVELY TARGETING THE EPIGENOME IN EMBRYONAL RHABDOMYOSARCOMA
Anna Mandel
Favorite
Mandell, Jonathan
University of Pittsburgh
(
P 025
)
INCREASED ALDH1A1 AND ATOX1 GENE EXPRESSION AND COPPER LEVELS IN CANINE OSTEOSARCOMA PATIENTS
Jonathan Mandell
Favorite
Mann, Gary
Department of Surgical Oncology, Roswell Park Comprehensive Cancer Center
(
P 218
)
PRIMARY PELVIC SOFT TISSUE SARCOMAS (PELVISARC): OUTCOMES IN A SERIES OF 401 PATIENTS FROM THE TRANSATLANTIC AUSTRALASIAN RETROPERITONEAL SARCOMA WORKING GROUP (TARPSWG)
Gary Mann
Favorite
Mansuy, Ludovic
CHRU Nacy
(
P 026
)
IS THERE STILL A PLACE FOR BONE MARROW SAMPLING IN VERY HIGH RISK EWING SARCOMA? ROLE OF FDG PET/CT IN THE INITIAL STAGING OF VERY HIGH RISK EWING SARCOMA IN A PROSPECTIVE PHASE II MULTICENTRIC STUDY.
Ludovic Mansuy
Favorite
Mantyh, John
Department of Medicine, Duke University
(
P 171
)
CANINE-DERIVED OSTEOSARCOMA ORGANOIDS MODEL TUMOR HETEROGENEITY AND CHEMOTHERAPY RESISTANCE
John Mantyh
Favorite
Maradit Kremers, Hilal
Mayo Clinic
(
P 302
)
SERUM METAL ION CONCENTRATIONS IN THE SETTING OF AN ONCOLOGIC ENDOPROSTHESIS: IS THERE CAUSE FOR CONCERN?
Hilal Maradit Kremers
Favorite
Marang-van de Mheen, Perla
Leiden University Medical Center
(
P 076
)
FOLLOW-UP AFTER CURATIVE SURGICAL TREATMENT OF SOFT-TISSUE SARCOMAS: PATIENTS RECEIVING MORE OR LESS VISITIS THAN PROTOCOL AND ASSOCIATIONS WITH RECURRENCE
Perla Marang-van de Mheen
Favorite
(
P 079
)
HEALTH-RELATED QUALITY OF LIFE OF BONE AND SOFT-TISSUE TUMOR PATIENTS AT TIME OF DIAGNOSIS
Perla Marang-van de Mheen
Favorite
Marcellus, Richard
Ontario Institute for Cancer Research
(
P 190
)
SELECTIVELY TARGETING THE EPIGENOME IN EMBRYONAL RHABDOMYOSARCOMA
Richard Marcellus
Favorite
(
P 191
)
SYNERGISTIC ACTIVITY OF PARP INHIBITORS IN COMBINATION WITH STANDARD CHEMOTHERAPY IN LEIOMYOSARCOMA
Richard Marcellus
Favorite
Marcilla, David
HU Virgen del Rocio
(
P 161
)
PALBOSARC: A PHASE II TRIAL OF PALBOCICLIB IN ADVANCED SARCOMA OVEREXPRESSING CDK4 GENE EXCLUDING DEDIFFERENTIATED LIPOSARCOMA (DD LPS): A STUDY FROM THE SPANISH GROUP FOR RESEARCH ON SARCOMA (GEIS).
David Marcilla
Favorite
Marcoux, Nicolas
Centre Hospitalier Universitaire de Québec
(
P 165
)
REAL- WORLD EXPERIENCE OF TYROSINE KINASE INHIBITORS IN PATIENTS WITH RECURRENT BONE TUMOURS (BT): A CANSARCC STUDY
Nicolas Marcoux
Favorite
Mariño-Enríquez, Adrian
Brigham and Women’s Hospital
(
P 099
)
CONCURRENT INHIBITION OF CDK2 ADDS TO THE ANTI-TUMOR ACTIVITY OF CDK4/6 INHIBITION IN GIST
Adrian Mariño-Enríquez
Favorite
Markovic, Svetomir
Mayo Clinic (Rochester)
(
P 289
)
MERKEL CELL CARCINOMA OF UNKNOWN PRIMARY: CLINICAL PRESENTATION AND OUTCOMES
Svetomir Markovic
Favorite
Marrari, Andrea
Rizzoli Orthopedic Institute IRCCS
(
P 031
)
PAZOPANIB IN ADVANCED BONE SARCOMA: A RETROSPECTIVE ANALYSIS OF RIZZOLI ORTHOPEDIC INSTITUTE
Andrea Marrari
Favorite
Marshall, Mark
Indiana University School of Medicine/Riley Hospital for Children
(
P 226
)
ASSESSING PREDICTIVE VALUE OF RNA-SEQ OF B4GALNT1 AND ST8SIA1 AS BIOMARKERS OF GD2 EXPRESSION IN PEDIATRIC SARCOMAS
Mark Marshall
Favorite
Martínez Bernal, Gala
Hospital Universitario Virgen del Rocío
(
P 267
)
EFFICACY OF SORAFENIB IN PRETREATED DESMOID TUMORS. EXPERIENCE OF A HIGH-VOLUME CENTER.
Gala Martínez Bernal
Favorite
Martínez, Jerónimo
Hospital Universitario Virgen de la Arrixaca
(
P 219
)
PROGNOSTIC VALUE OF HEMATOLOGICAL MARKERS IN LEIOMYOSARCOMA
Jerónimo Martínez
Favorite
Märten, Angela
Boehringer Ingelheim International GmbH
(
P 163
)
PHASE IA/IB, DOSE-ESCALATION/EXPANSION STUDY OF THE MURINE DOUBLE MINUTE 2–TUMOR PROTEIN 53 ANTAGONIST BI 907828 IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITORS IN PATIENTS WITH ADVANCED SOLID TUMORS
Angela Märten
Favorite
Martín-Broto, Javier
Fundacíon Jiménez Díaz University Hospital, ATBSARC lab in General Hospital of Villalba, IIS-FJD, Madrid, Spain
(
P 038
)
TENOSYNOVIAL GIANT CELL TUMOR OBSERVATIONAL PLATFORM PROJECT (TOPP): 2-YEAR OBSERVATIONAL SUB-ANALYSIS OF AGE AND PATIENT-REPORTED OUTCOMES FROM AN EU/US PROSPECTIVE REGISTRY
Javier Martín-Broto
Favorite
(
P 113
)
PROGNOSTIC AND/OR PREDICTIVE VALUE OF EXON 11 MUTATIONS IN TUMOR RESPONSE TO IMATINIB IN METASTATIC GASTROINTESTINAL STROMAL TUMOR :RETROSPECTIVE ANALYSIS OF A MULTICENTRIC NATIONAL REGISTRY
Javier Martín-Broto
Favorite
(
P 116
)
SAFETY AND EFFICACY OF VIMSELTINIB IN TENOSYNOVIAL GIANT CELL TUMOUR: LONG-TERM PHASE 1 UPDATE
Javier Martín-Broto
Favorite
(
P 135
)
PREDICTIVE VALUE OF ISG15 AND PPAP2B IN SOLITARY FIBROUS TUMOR TREATED WITH SUNITINIB AND NIVOLUMAB: A CORRELATIVE STUDY FROM IMMUNOSARC, A SPANISH GROUP FOR RESEARCH ON SARCOMA (GEIS) PHASE II TRIAL
Javier Martín-Broto
Favorite
(
P 161
)
PALBOSARC: A PHASE II TRIAL OF PALBOCICLIB IN ADVANCED SARCOMA OVEREXPRESSING CDK4 GENE EXCLUDING DEDIFFERENTIATED LIPOSARCOMA (DD LPS): A STUDY FROM THE SPANISH GROUP FOR RESEARCH ON SARCOMA (GEIS).
Javier Martín-Broto
Favorite
(
P 204
)
PERCEPTIONS AND MANAGEMENT PRACTICES OF SARCOMA EXPERTS ABOUT SOFT TISSUE SARCOMA PATIENTS WITH ISOLATED LUNG METASTASES ACROSS EUROPE
Javier Martín-Broto
Favorite
(
P 225
)
TRABECTEDIN WITH CONCOMITANT RADIATION THERAPY FOR PATIENTS WITH RESECTABLE RETROPERITONEAL LIPOSARCOMA OR LEIOMYOSARCOMA: A PHASE I/II TRIAL OF SPANISH (GEIS), ITALIAN (ISG) AND FRENCH (FSG) GROUPS
Javier Martín-Broto
Favorite
(
P 268
)
INITIAL RESULTS OF PHASE 2/3 TRIAL OF AL102 FOR TREATMENT OF DESMOID TUMORS (DT)
Javier Martín-Broto
Favorite
(
P 314
)
A PHASE II/III, RANDOMIZED, OPEN LABEL, MULTICENTER STUDY OF THE MDM2–P53 ANTAGONIST BI 907828 VS DOXORUBICIN IN THE FIRST-LINE TREATMENT OF PATIENTS WITH DEDIFFERENTIATED LIPOSARCOMA: BRIGHTLINE-1
Javier Martín-Broto
Favorite
(
P 315
)
A RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2 TRIAL OF INBRX-109 IN UNRESECTABLE OR METASTATIC CONVENTIONAL CHONDROSARCOMA
Javier Martín-Broto
Favorite
Martínez-Delfrade, Íñigo
Department of Medical Oncology, Ramón y Cajal University Hospital
(
P 157
)
MOLECULAR SCREENING OF ADVANCED SARCOMAS THROUGH NEXT-GENERATION SEQUENCING IN A TERTIARY UNIVERSITY HOSPITAL
Íñigo Martínez-Delfrade
Favorite
Martinez-Garcia, Jeronimo
Hospital clínico universitario virgen de la arrixaca
(
P 119
)
SURGICAL MANAGEMENT OF GASTROINTESTINAL STROMAL TUMOURS SARCOMATOSIS (GISTOSIS). A RETROSPECTIVE MULTI-INSTITUTIONAL STUDY
Jeronimo Martinez-Garcia
Favorite
(
P 161
)
PALBOSARC: A PHASE II TRIAL OF PALBOCICLIB IN ADVANCED SARCOMA OVEREXPRESSING CDK4 GENE EXCLUDING DEDIFFERENTIATED LIPOSARCOMA (DD LPS): A STUDY FROM THE SPANISH GROUP FOR RESEARCH ON SARCOMA (GEIS).
Jeronimo Martinez-Garcia
Favorite
(
P 318
)
NEOADJUVANT CHEMORADIOTHERAPY IN ADVANCED SOFT TISSUE SARCOMA. UPDATED NASAR STUDY
Jeronimo Martinez-Garcia
Favorite
Martinez-Trufero, Javier
HU Miguel Servet
(
P 135
)
PREDICTIVE VALUE OF ISG15 AND PPAP2B IN SOLITARY FIBROUS TUMOR TREATED WITH SUNITINIB AND NIVOLUMAB: A CORRELATIVE STUDY FROM IMMUNOSARC, A SPANISH GROUP FOR RESEARCH ON SARCOMA (GEIS) PHASE II TRIAL
Javier Martinez-Trufero
Favorite
(
P 161
)
PALBOSARC: A PHASE II TRIAL OF PALBOCICLIB IN ADVANCED SARCOMA OVEREXPRESSING CDK4 GENE EXCLUDING DEDIFFERENTIATED LIPOSARCOMA (DD LPS): A STUDY FROM THE SPANISH GROUP FOR RESEARCH ON SARCOMA (GEIS).
Javier Martinez-Trufero
Favorite
Martini, Silvia
Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
(
P 188
)
PRELIMINARY ASSESSMENT OF CIRCULATING INFLAMMATORY CYTOKINES IN EPITHELIOID HEMANGIOENDOTHELIOMA (EHE) PATIENTS AND IN AN EHE PATIENT-DERIVED XENOGRAFT BEFORE AND AFTER DOXORUBICIN AND SIROLIMUS
Silvia Martini
Favorite
Marti, Roberto
Hospital clínico universitario
(
P 119
)
SURGICAL MANAGEMENT OF GASTROINTESTINAL STROMAL TUMOURS SARCOMATOSIS (GISTOSIS). A RETROSPECTIVE MULTI-INSTITUTIONAL STUDY
Roberto Marti
Favorite
Martorano, Domenico
Radiology Service, CTO Hospital, AOU Città della Salute e della Scienza di Torino
(
P 058
)
SARCOPENIA AS A NEGATIVE PROGNOSTIC FACTOR IN LOCALIZED EXTREMITIES/TRUNK WALL SOFT TISSUE SARCOMAS
Domenico Martorano
Favorite
Marx, Alexander
Institue of Pathology, Mannheim University Medical Center
(
P 264
)
DESMOID AND TRAUMA: REAL INCIDENCE AND MEDICOLEGAL ASPECTS OF CAUSALITY
Alexander Marx
Favorite
Mascarenhas, Leo
Children's Hospital Los Angeles, University of Southern California Keck School of Medicine
(
P 023
)
FACTORS ASSOCIATED WITH LOCAL CONTROL AND SURVIVAL IN LOCALIZED EWING SARCOMA PATIENTS TREATED WITH SURGERY ON AEWS1031: A REPORT FROM THE CHILDRENS ONCOLOGY GROUP
Leo Mascarenhas
Favorite
(
P 037
)
SURVIVAL OUTCOMES AND POST-SURGICAL MORBIDITY BASED ON SURGICAL APPROACH TO PULMONARY METASTASECTOMY IN PATIENTS WITH OSTEOSARCOMA
Leo Mascarenhas
Favorite
(
P 045
)
DETECTION OF CELL-FREE TUMOR DNA IN PATIENTS WITH NEWLY DIAGNOSED PEDIATRIC BONE AND SOFT TISSUE SARCOMAS
Leo Mascarenhas
Favorite
Masters, Brian
Duke University School of Medicine
(
P 254
)
THE IMPACT OF MST (HIPPO KINASE) INHIBITION ON CHROMATIN ACCESSIBILITY AND ONCOGENIC PHENOTYPES IN FUSION-POSITIVE RHABDOMYOSARCOMA
Brian Masters
Favorite
Mata, Cristina
Hospital General Universitario Gregorio Marañón
(
P 148
)
ANALYSIS OF REECUR TRIAL DATA TO EVALUATE POTENTIAL PROGNOSTIC FACTORS IN RECURRENT AND PRIMARY REFRACTORY EWING SARCOMA (RR-ES)
Cristina Mata
Favorite
Mate, Kedar
McGill University Health Centre
(
P 064
)
A SYSTEMATIC REVIEW OF PATIENT-REPORTED OUTCOMES USED TO MEASURE HEALTH-RELATED QUALITY OF LIFE IN SOFT-TISSUE SARCOMA
Kedar Mate
Favorite
(
P 082
)
PATIENT-REPORTED OUTCOME MEASURES TO MEASURE HEALTH-RELATED QUALITY OF LIFE IN PEOPLE WITH SOFT-TISSUE SARCOMA: A SYSTEMATIC REVIEW OF MEASUREMENT PROPERTIES OF PATIENT-REPORTED OUTCOMES
Kedar Mate
Favorite
(
P 092
)
THE SARCOMA-SPECIFIC QUALITY OF LIFE STUDY (SARC-QOL): IDENTIFYING KEY DOMAINS OF HEALTH-RELATED QUALITY OF LIFE IN ADULT PATIENTS WITH EXTREMITY SOFT TISSUE SARCOMA
Kedar Mate
Favorite
Mateo-Carrasco, Hector
University College London Hospital
(
P 271
)
ORAL VINORELBINE IN DESMOID TUMOURS; A SINGLE CENTRE RETROSPECTIVE ANALYSIS
Hector Mateo-Carrasco
Favorite
Mathew, Grace
MD Anderson Cancer Center
(
P 013
)
A PHASE 2 TRIAL OF CETUXIMAB FOR PATIENTS WITH LOCALLY ADVANCED/METASTATIC CHORDOMA
Grace Mathew
Favorite
Matsui, Yoshiyuki
Department of Urology and Retroperitoneal Surgery, National Cancer Center Hospital
(
P 147
)
ANALYSIS OF INFLAMMATORY BIOMARKERS AS PREDICTORS OF TREATMENT EFFICACY IN SOFT TISSUE SARCOMA TREATED WITH TRABECTEDIN
Yoshiyuki Matsui
Favorite
Matsumoto, Yoshihiro
Kyushu University Department of Orthopaedic Surgery
(
P 125
)
EFFECTIVENESS OF PERIPHERAL BLOOD IMMUNE-RELATED MARKERS IN SELECTING NOVEL THERAPEUTIC AGENTS FOR ADVANCED SOFT TISSUE SARCOMA
Yoshihiro Matsumoto
Favorite
Mauer, Elizabeth
Tempus Labs
(
P 039
)
THE GENOMIC AND IMMUNE LANDSCAPE OF OSTEOSARCOMA
Elizabeth Mauer
Favorite
Maurage, Claude-Alain
CHRU LILLE
(
P 080
)
INTRACRANIAL SOLITARY FIBROUS TUMOUR/HEMANGIOPERICYTOMA MANAGEMENT: A FRENCH MULTICENTRE RETROSPECTIVE STUDY
Claude-Alain Maurage
Favorite
Mavroeidi, Ilektra
Department of Medical Oncology, West German Cancer Center, University Hospital Essen
(
P 176
)
FIBROBLAST ACTIVATION PROTEIN ALPHA AS THERANOSTIC TARGET IN SARCOMA
Ilektra Mavroeidi
Favorite
Maxim, Peter
Department of Radiation Oncology, University of California Irvine
(
P 199
)
A STUDY OF PRE- AND POST-TREATMENT NEUTROPHIL COUNTS, LYMPHOCYTE COUNTS, AND NEUTROPHIL-TO-LYMPHOCYTE RATIOS IN PATIENTS WITH SOFT TISSUE SARCOMA UNDERGOING RADIOTHERAPY
Peter Maxim
Favorite
Mayo, Nancy
McGill University Health Centre
(
P 092
)
THE SARCOMA-SPECIFIC QUALITY OF LIFE STUDY (SARC-QOL): IDENTIFYING KEY DOMAINS OF HEALTH-RELATED QUALITY OF LIFE IN ADULT PATIENTS WITH EXTREMITY SOFT TISSUE SARCOMA
Nancy Mayo
Favorite
Mazzocca, Alessandro
Policlinico Universitario Campus Bio-medico
(
P 162
)
PAZOPANIB IN THE REAL-WORLD SETTING: DATA FROM THE ITALIAN NATIONAL REGISTRY
Alessandro Mazzocca
Favorite
Mazzola, Emanuele
Dana-Farber Cancer Institute
(
P 143
)
A PHASE 1 B LEAD-IN TO A RANDOMIZED PHASE 2 TRIAL OF LURBINECTEDIN PLUS DOXORUBICIN IN LEIOMYOSARCOMA (LMS): RESULTS FROM THE PHASE 1B SOFT-TISSUE SARCOMA (STS) LEAD-IN
Emanuele Mazzola
Favorite
McAlpine, Cheryl
Adaptimmune
(
P 127
)
IDENTIFYING MAGE-A4-POSITIVE TUMORS FOR SPEAR T-CELL THERAPIES IN HLA-A*02-ELIGIBLE PATIENTS
Cheryl McAlpine
Favorite
McCabe, Martin
University of Manchester
(
P 148
)
ANALYSIS OF REECUR TRIAL DATA TO EVALUATE POTENTIAL PROGNOSTIC FACTORS IN RECURRENT AND PRIMARY REFRACTORY EWING SARCOMA (RR-ES)
Martin McCabe
Favorite
McCowage, Geoffrey
Sydney Children’s Hospitals Network
(
P 043
)
A MULTICENTER, OPEN-LABEL, RANDOMIZED, PHASE 2 STUDY OF LENVATINIB IN COMBINATION WITH IFOSFAMIDE AND ETOPOSIDE VERSUS IFOSFAMIDE AND ETOPOSIDE IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS WITH RELAPSED OR REFRACTORY OSTEOSARCOMA
Geoffrey McCowage
Favorite
McCrimmon, Laura
Aberdeen University School of Medicine and Dentistry
(
P 073
)
EVALUATING DISTRESS AND THE PATIENT EXPERIENCE OF SARCOMA PATIENTS IN THE WEST OF SCOTLAND
Laura McCrimmon
Favorite
McDermott, Ray
St. Vincent’s University Hospital and University College Dublin
(
P 107
)
LONG-TERM EFFICACY AND SAFETY OF LAROTRECTINIB IN ADULT PATIENTS WITH TRK FUSION SARCOMAS
Ray McDermott
Favorite
McGough, Richard
University of Pittsburgh Medical Center
(
P 046
)
EVALUATION OF INTRAOPERATIVE TUMOR MARGINS IN SARCOMA WITH FLUORESCENT DYE IMAGING: A PRELIMINARY ANALYSIS OF RESULTS
Richard McGough
Favorite
(
P 087
)
RATING THE EFFICACY OF DIAGNOSTIC IMAGING STUDIES PERFORMED FOR THE WORK-UP OF MUSCULOSKELETAL MASSES
Richard McGough
Favorite
McGuigan, Sandra
Adaptimmune
(
P 127
)
IDENTIFYING MAGE-A4-POSITIVE TUMORS FOR SPEAR T-CELL THERAPIES IN HLA-A*02-ELIGIBLE PATIENTS
Sandra McGuigan
Favorite
McKean, Meredith
Sarah Cannon and HCA Research Institute
(
P 313
)
A PHASE 2, MULTICENTER, OPEN-LABEL BASKET TRIAL OF NAB-SIROLIMUS FOR PATIENTS WITH MALIGNANT SOLID TUMORS HARBORING PATHOGENIC INACTIVATING ALTERATIONS IN TSC1 OR TSC2 GENES (PRECISION I)
Meredith McKean
Favorite
McKenzie, Jodi
Eisai Inc.
(
P 043
)
A MULTICENTER, OPEN-LABEL, RANDOMIZED, PHASE 2 STUDY OF LENVATINIB IN COMBINATION WITH IFOSFAMIDE AND ETOPOSIDE VERSUS IFOSFAMIDE AND ETOPOSIDE IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS WITH RELAPSED OR REFRACTORY OSTEOSARCOMA
Jodi McKenzie
Favorite
McKone, Elizabeth
Mayo Clinic
(
P 201
)
LOCAL CONTROL AND SURVIVAL OUTCOMES IN PEDIATRIC NON-RHABDOMYOSARCOMA SOFT TISSUE SARCOMA: THE MAYO CLINIC EXPERIENCE
Elizabeth McKone
Favorite
McLaughlin, Mariel
University of South Florida Morsani College of Medicine
(
P 305
)
THE INCIDENCE OF THROMBOEMBOLIC EVENTS DURING HOSPITALIZATIONS FOLLOWING SURGICAL RESECTION OF LOWER EXTREMITY SARCOMAS IN CHILDREN: UTILIZING THE PEDIATRIC HEALTH INFORMATION SYSTEM (PHIS) DATABASE
Mariel McLaughlin
Favorite
Medina, Vicente
HU Canarias
(
P 225
)
TRABECTEDIN WITH CONCOMITANT RADIATION THERAPY FOR PATIENTS WITH RESECTABLE RETROPERITONEAL LIPOSARCOMA OR LEIOMYOSARCOMA: A PHASE I/II TRIAL OF SPANISH (GEIS), ITALIAN (ISG) AND FRENCH (FSG) GROUPS
Vicente Medina
Favorite
Mehtsun, Winta
University of California, San Diego
(
P 100
)
COPY NUMBER ALTERATIONS IN CDKN2A AND CDKN2B ARE ASSOCIATED WITH WORSENED OVERALL SURVIVAL IN PATIENTS WITH GIST
Winta Mehtsun
Favorite
Mencaglia, Emanuela
Humanitas Clinical and Research Center, IRCCS, Rozzano, 20089, Italy.
(
P 08
)
HOW TO DEVELOP AN ADOLESCENT AND YOUNG PROGRAM IN AN ADULT CANCER CENTER: THE HUMANITAS RESEARCH HOSPITAL EXPERIENCE
Emanuela Mencaglia
Favorite
Mendes, Elizabeth
Duke University School of Medicine
(
P 254
)
THE IMPACT OF MST (HIPPO KINASE) INHIBITION ON CHROMATIN ACCESSIBILITY AND ONCOGENIC PHENOTYPES IN FUSION-POSITIVE RHABDOMYOSARCOMA
Elizabeth Mendes
Favorite
Menge, Franka
Div.of Surgical Oncology and Thoracic Surgery, Mannheim University Medical Center, University of Heidelberg, Germany
(
P 264
)
DESMOID AND TRAUMA: REAL INCIDENCE AND MEDICOLEGAL ASPECTS OF CAUSALITY
Franka Menge
Favorite
Meng, Fanfei
Shanghai OrigiMed Co., Ltd
(
P 021
)
DISTINCT GENOMIC FEATURES BETWEEN OSTEOSARCOMAS FIRSTLY METASTASING TO BONE AND TO LUNG
Fanfei Meng
Favorite
Mercatali, Laura
Clinical and Experimental Oncology, Immunotherapy, Rare Cancers and Biological Resource Center, IRCCS Istituto Romagnolo Per Lo Studio Dei Tumori (IRST) "Dino Amadori", Meldola, Italy.
(
P 195
)
THE STRATEGIC ROLE OF 3D CULTURE SYSTEMS AND ZEBRAFISH NEAR-PATIENTS PRECLINICAL PLATFORMS AS PREDICTIVE TOOLS OF CHEMOTHERAPY RESPONSE FOR SARCOMA
Laura Mercatali
Favorite
(
P 250
)
SYSTEMIC INFLAMMATORY INDICES IN SECOND LINE SOFT TISSUE SARCOMAS PATIENTS: FOCUS ON LYMPHOCYTE/MONOCYTE RATIO AND TRABECTEDIN ACTIVITY
Laura Mercatali
Favorite
Meredith, Carly
St. Jude Children's Research Hospital
(
P 012
)
ACUTE CARDIAC CHANGES IN PEDIATRIC AND YOUNG ADULT SOLID TUMOR PATIENTS TREATED WITH TYROSINE KINASE INHIBITORS
Carly Meredith
Favorite
Merjaneh, Nawal
Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center
(
P 118
)
SOMATOSTATIN RECEPTOR TYPE 2 EXPRESSION IN SARCOMA
Nawal Merjaneh
Favorite
Merle, Candice
Institut Curie
(
P 253
)
THE IMPACT OF CELL FUSION IN LEIOMYOSARCOMA ONCOGENESIS
Candice Merle
Favorite
Merlini, Alessandra
Department of Oncology, University of Turin
(
P 058
)
SARCOPENIA AS A NEGATIVE PROGNOSTIC FACTOR IN LOCALIZED EXTREMITIES/TRUNK WALL SOFT TISSUE SARCOMAS
Alessandra Merlini
Favorite
Merriam, Priscilla
Dana-Farber Cancer Institute
(
P 143
)
A PHASE 1 B LEAD-IN TO A RANDOMIZED PHASE 2 TRIAL OF LURBINECTEDIN PLUS DOXORUBICIN IN LEIOMYOSARCOMA (LMS): RESULTS FROM THE PHASE 1B SOFT-TISSUE SARCOMA (STS) LEAD-IN
Priscilla Merriam
Favorite
(
P 214
)
EXPERIENCE OF MANAGEMENT FOR LOCALIZED PARATESTICULAR LIPOSARCOMA: A SINGLE INSTITUTION COHORT
Priscilla Merriam
Favorite
Mertens, Fredrik
Lund University
(
P 242
)
LIPOSARCOMAS WITH 12Q AMPLIFICATION - CAN GENETIC CHANGES DISCLOSE THE DEVELOPMENT AND ORIGIN OF RING CHROMOSOMES?
Fredrik Mertens
Favorite
Mesirov, Jill
University of California, San Diego
(
P 100
)
COPY NUMBER ALTERATIONS IN CDKN2A AND CDKN2B ARE ASSOCIATED WITH WORSENED OVERALL SURVIVAL IN PATIENTS WITH GIST
Jill Mesirov
Favorite
Mesko, Nathan
Cleveland Clinic
(
P 071
)
DEVELOPMENT OF A COLLABORATIVE SARCOMA REGISTRY: STRATEGIES TO DECREASE PROVIDER BURDEN AND INCREASE ENGAGEMENT
Nathan Mesko
Favorite
Messer, Emily
UC San Diego Moores Cancer Center
(
P 096
)
AN OPEN-LABEL, PHASE 2 EFFICACY STUDY OF TEMOZOLOMIDE IN ADVANCED SUCCINATE DEHYDROGENASE-MUTANT/DEFICIENT GASTROINTESTINAL STROMAL TUMOR
Emily Messer
Favorite
Messer, Karen
UC San Diego Moores Cancer Center
(
P 096
)
AN OPEN-LABEL, PHASE 2 EFFICACY STUDY OF TEMOZOLOMIDE IN ADVANCED SUCCINATE DEHYDROGENASE-MUTANT/DEFICIENT GASTROINTESTINAL STROMAL TUMOR
Karen Messer
Favorite
Messiou, Christina
The Royal Marsden NHS Trust
(
P 061
)
UNRAVELLING THE HETEROGENEITY OF THE IMMUNE MICROENVIRONMENT IN STS USING QUANTITATIVE MRI
Christina Messiou
Favorite
(
P 085
)
RADIATION ASSOCIATED ANGIOSARCOMAS OF THE BREAST: MULTIFOCALITY WARRANTS AGGRESSIVE ONCOLOGICAL STRATEGY
Christina Messiou
Favorite
Metallo, Christian
Salk Institute
(
P 096
)
AN OPEN-LABEL, PHASE 2 EFFICACY STUDY OF TEMOZOLOMIDE IN ADVANCED SUCCINATE DEHYDROGENASE-MUTANT/DEFICIENT GASTROINTESTINAL STROMAL TUMOR
Christian Metallo
Favorite
Metts, Jonathan
Johns Hopkins All Children's Hospital
(
P 237
)
EVOLUTIONARILY INSPIRED THERAPY FOR NEWLY DIAGNOSED, METASTATIC, FUSION POSITIVE RHABDOMYOSARCOMA, TRIAL IN PROGRES, NCT04388839, A REPORT FROM THE NATIONAL PEDIATRIC CANCER FOUNDATION
Jonathan Metts
Favorite
(
P 305
)
THE INCIDENCE OF THROMBOEMBOLIC EVENTS DURING HOSPITALIZATIONS FOLLOWING SURGICAL RESECTION OF LOWER EXTREMITY SARCOMAS IN CHILDREN: UTILIZING THE PEDIATRIC HEALTH INFORMATION SYSTEM (PHIS) DATABASE
Jonathan Metts
Favorite
Meurgey, Alexandra
Department of Pathology, Centre Léon Bérard
(
P 189
)
PROGNOSTIC IMPACT OF NEW YORK ESOPHAGEAL SQUAMOUS CELL CARCINOMA-1 EXPRESSION AND HUMAN LEUKOCYTE ANTIGEN SUBTYPES IN METASTATIC SYNOVIAL SARCOMA
Alexandra Meurgey
Favorite
(
P 238
)
EXPANDING THE MOLECULAR SPECTRUM OF GIANT CELL TUMORS.
Alexandra Meurgey
Favorite
Meyers, Paul
Memorial Sloan Kettering Cancer Center
(
P 154
)
IRINOTECAN DOSE SCHEDULE FOR THE TREATMENT OF RECURRENT EWING SARCOMA
Paul Meyers
Favorite
Meza-Zepeda, Leonardo
Oslo University Hospital
(
P 114
)
PROGNOSTIC IMPACT OF CIRCULATING TUMOR DNA DETECTION IN FIRST-LINE TREATMENT OF ADVANCED GASTROINTESTINAL STROMAL TUMOR
Leonardo Meza-Zepeda
Favorite
Miah, Aisha
The Royal Marsden NHS Foundation Trust
(
P 085
)
RADIATION ASSOCIATED ANGIOSARCOMAS OF THE BREAST: MULTIFOCALITY WARRANTS AGGRESSIVE ONCOLOGICAL STRATEGY
Aisha Miah
Favorite
(
P 152
)
FINAL RESULTS OF GEMMK: A PHASE I TRIAL OF GEMCITABINE AND PEMBROLIZUMAB IN PATIENTS WITH LEIOMYOSARCOMA AND UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Aisha Miah
Favorite
MIAO, CHENGLI
Department of Retroperitoneal Tumors Surgery, Peking University International Hospital
(
P 213
)
EPITHELIOID INFLAMMATORY MYOFIBROBLASTIC SARCOMA WITH LEUKEMOID REACTION
CHENGLI MIAO
Favorite
Miao, Chengli
Department of Retroperitoneal Tumor Surgery, Peking University International Hospital
(
P 222
)
SURGICAL RESECTION OF ABDOMINOPELVIC AGGRESSIVE ANGIOMYXOMA: A RETROSPECTIVE REVIEW OF 12 CONSECUTIVE CASES
Chengli Miao
Favorite
Miceli, Rosalba
Department of Clinical Epidemiology and Trial Organization, Fondazione IRCCS Istituto Nazionale dei Tumori
(
P 052
)
PATHOLOGICAL AND RADIOLOGICAL RESPONSE AFTER NEOADJUVANT TREATMENTS IN PRIMARY RESECTABLE MYXOFIBROSARCOMA AND UNDIFFERENTIATED PLEOMORPHIC SARCOMA OF THE EXTREMITIES AND TRUNK WALL
Rosalba Miceli
Favorite
(
P 179
)
IMMUNOSUPPRESSIVE MYELOID CELLS ARE INCREASED IN PATIENTS WITH SOFT TISSUE SARCOMA (STS) AND ARE NEGATIVELY ASSOCIATED WITH SURVIVAL
Rosalba Miceli
Favorite
Michal, Michael
Charles University, Faculty of Medicine in Plzen, Czech Republic
(
P 231
)
COMPREHENSIVE MOLECULAR PROFILING OF FOLLICULAR DENDRITIC CELL SARCOMA
Michael Michal
Favorite
Michal, Michal
Charles University, Faculty of Medicine in Plzen, Czech Republic
(
P 231
)
COMPREHENSIVE MOLECULAR PROFILING OF FOLLICULAR DENDRITIC CELL SARCOMA
Michal Michal
Favorite
Michelagnoli, Maria
Sarcoma Department, University College London Hospital
(
P 271
)
ORAL VINORELBINE IN DESMOID TUMOURS; A SINGLE CENTRE RETROSPECTIVE ANALYSIS
Maria Michelagnoli
Favorite
Mikhak, Zamaneh
Cogent Biosciences
(
P 320
)
PEAK STUDY: A PHASE 3 RANDOMIZED, OPEN-LABEL, MULTICENTER CLINICAL STUDY OF BEZUCLASTINIB (CGT9486) AND SUNITINIB VERSUS SUNITINIB IN PATIENTS WITH GASTROINTESTINAL STROMAL TUMORS
Zamaneh Mikhak
Favorite
Mikkers, Harald
LUMC
(
P 255
)
TRUNCATED FOS REDUCES OSTEOGENIC DIFFERENTIATION CAPACITY IN OSTEOID OSTEOMA AND OSTEOBLASTOMA
Harald Mikkers
Favorite
Milano, Giuseppe Maria
Department of Hematology/Oncology, Ospedale Pediatrico Bambino Gesù IRCCS, Roma, Italy
(
P 016
)
ACTIVITY OF CHEMOTHERAPY IN MESENCHYMAL CHONDROSARCOMA: A MULTICENTRE RETROSPECTIVE ANALYSIS WITHIN THE ITALIAN SARCOMA GROUP
Giuseppe Maria Milano
Favorite
Milhem, Mohammed
University of Iowa Hospitals & Clinics
(
P 159
)
NEOADJUVANT INTRATUMORAL HIGH DOSE TALIMOGENE LAHERPAREPVEC (TVEC) WITH CONCURRENT RADIATION IN HIGH-RISK EXTREMITY AND TRUNK SOFT-TISSUE SARCOMAS
Mohammed Milhem
Favorite
(
P 160
)
NEOADJUVANT PHARMACOLOGICAL ASCORBATE WITH CONCURRENT RADIATION IN LOCALLY ADVANCED SOFT-TISSUE SARCOMA OF EXTREMITY/TRUNK AND RETROPERITONEUM
Mohammed Milhem
Favorite
Millar, Shontelle
University of the West Indies Cavehill Campus Barbados
(
P 205
)
PREOPERATIVE CHEMORADIATION (MODIFIED EILBER PROTOCOL) VERSUS NEOADJUVANT/ ADJUVANT RADIOTHERAPY FOR SOFT TISSUE EXTREMITY SARCOMAS: A POPULATION BASED ANALYSIS IN ALBERTA
Shontelle Millar
Favorite
Miller, Benjamin
University of Iowa
(
P 071
)
DEVELOPMENT OF A COLLABORATIVE SARCOMA REGISTRY: STRATEGIES TO DECREASE PROVIDER BURDEN AND INCREASE ENGAGEMENT
Benjamin Miller
Favorite
(
P 159
)
NEOADJUVANT INTRATUMORAL HIGH DOSE TALIMOGENE LAHERPAREPVEC (TVEC) WITH CONCURRENT RADIATION IN HIGH-RISK EXTREMITY AND TRUNK SOFT-TISSUE SARCOMAS
Benjamin Miller
Favorite
(
P 160
)
NEOADJUVANT PHARMACOLOGICAL ASCORBATE WITH CONCURRENT RADIATION IN LOCALLY ADVANCED SOFT-TISSUE SARCOMA OF EXTREMITY/TRUNK AND RETROPERITONEUM
Benjamin Miller
Favorite
Miller, Elizabeth
Regeneron Pharmaceuticals
(
P 131
)
MUCIN 16 (CANCER ANTIGEN 125) EXPRESSION IN EPITHELIOID SARCOMA LEADS TO SINGLE-PATIENT STUDY WITH BISPECIFIC T-CELL ENGAGER UBAMATAMAB (MUCIN16-CD3): A BENCH-TO-BEDSIDE EXPERIENCE
Elizabeth Miller
Favorite
Mills, Denise
Hospital for Sick Children and University of Toronto
(
P 131
)
MUCIN 16 (CANCER ANTIGEN 125) EXPRESSION IN EPITHELIOID SARCOMA LEADS TO SINGLE-PATIENT STUDY WITH BISPECIFIC T-CELL ENGAGER UBAMATAMAB (MUCIN16-CD3): A BENCH-TO-BEDSIDE EXPERIENCE
Denise Mills
Favorite
Mills, Sherri
Foundation Medicine Inc.
(
P 177
)
GENOMIC LANDSCAPE OF RARE EWSR1 FUSIONS
Sherri Mills
Favorite
(
P 256
)
TUMOR MUTATIONAL BURDEN AND MICROSATELLITE INSTABILITY IN LEIOMYOSARCOMA
Sherri Mills
Favorite
Milovanova, Ekaterina
Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan (IT)
(
P 203
)
MULTIDISCIPLINARY APPROACH OF ADVANCED-STAGE ALVEOLAR RHABDOMYOSARCOMA OF THE MAXILLARY SINUS IN ADULTS: A CASE REPORT
Ekaterina Milovanova
Favorite
Mimpen, Jolet
University of Oxford
(
P 252
)
THE GENOMIC LANDSCAPE OF CLEAR CELL SARCOMA RESEARCH INITIATIVE
Jolet Mimpen
Favorite
Mintautas, Ingrid
C4 Therapeutics
(
P 312
)
A PHASE 1/2 STUDY OF CFT8634, A NOVEL BIFUNCTIONAL DEGRADATION ACTIVATING COMPOUND (BIDAC) DEGRADER OF BRD9, IN SYNOVIAL SARCOMA AND SMARCB1-NULL TUMORS
Ingrid Mintautas
Favorite
Mir, Olivier
INSTITUT GUSTAVE ROUSSY
(
P 217
)
PLANNED MARGINAL (R1) RESECTION IN PRIMARY RETROPERITONEAL SARCOMAS: RETROSPECTIVE SERIES ON 168 PATIENTS FROM A NATIONAL SPECIALIZED REFERRAL CENTER
Olivier Mir
Favorite
Miserocchi, Giacomo
Osteoncology Unit, Bioscience Laboratory, IRCCS Istituto Romagnolo Per Lo Studio Dei Tumori (IRST) "Dino Amadori", Meldola, Italy
(
P 195
)
THE STRATEGIC ROLE OF 3D CULTURE SYSTEMS AND ZEBRAFISH NEAR-PATIENTS PRECLINICAL PLATFORMS AS PREDICTIVE TOOLS OF CHEMOTHERAPY RESPONSE FOR SARCOMA
Giacomo Miserocchi
Favorite
(
P 250
)
SYSTEMIC INFLAMMATORY INDICES IN SECOND LINE SOFT TISSUE SARCOMAS PATIENTS: FOCUS ON LYMPHOCYTE/MONOCYTE RATIO AND TRABECTEDIN ACTIVITY
Giacomo Miserocchi
Favorite
Misir, Sam
Zentalis
(
P 144
)
A PHASE 1/2 DOSE ESCALATION/EXPANSION STUDY OF ZN-C3 PLUS GEMCITABINE IN RELAPSED/REFRACTORY OSTEOSARCOMA
Sam Misir
Favorite
Mitchell, Shaunica
Cogent Biosciences
(
P 320
)
PEAK STUDY: A PHASE 3 RANDOMIZED, OPEN-LABEL, MULTICENTER CLINICAL STUDY OF BEZUCLASTINIB (CGT9486) AND SUNITINIB VERSUS SUNITINIB IN PATIENTS WITH GASTROINTESTINAL STROMAL TUMORS
Shaunica Mitchell
Favorite
Mitra, Shamik
Lund University
(
P 242
)
LIPOSARCOMAS WITH 12Q AMPLIFICATION - CAN GENETIC CHANGES DISCLOSE THE DEVELOPMENT AND ORIGIN OF RING CHROMOSOMES?
Shamik Mitra
Favorite
Mixon, Arianna
Dallas Fort Worth Sarcoma Group
(
P 095
)
A COLLABORATIVE MULTIDISCIPLINARY APPROACH MAY LEAD TO ENHANCED CLINICAL OUTCOMES AND QUALITY OF CARE FOR PATIENTS WITH DIFFUSE TGCT
Arianna Mixon
Favorite
(
P 236
)
EVALUATION OF HISTOLOGIC CHANGES OF TENOSYNOVIAL GIANT CELL TUMORS FOLLOWING TREATMENT WITH PEXIDARTINIB
Arianna Mixon
Favorite
(
P 248
)
RESULTS OF A NEOADJUVANT REGIMEN USING A FIXED DOSE OF ADRIAMYCIN AS AN ELECTRON AFFINIC AGENT WITH 27GY FOLLOWED BY WIDE LOCAL RESECTION OF SOFT TISSUE SARCOMAS
Arianna Mixon
Favorite
(
P 297
)
PREOPERATIVE EMBOLIZATION TO REDUCE THE RISK OF HEMORRHAGE FOR HEMANGIOPERICYTOMA RESECTION
Arianna Mixon
Favorite
Miyagi, Ryo
Department of Orthopaedic Surgery, Tokushima Prefectural Central Hospital
(
P 275
)
ASSESSMENT OF SURGICAL MARGIN CLASSIFICATION FOR SOFT TISSUE SARCOMA: DEFINITIONS OF ADEQUATE MARGINS SYSTEM FOR PLANNING AND EVALUATION
Ryo Miyagi
Favorite
Miyakoshi, Naohisa
Akita University Graduate School of Medicine
(
P 084
)
PROGNOSTIC FACTORS IN PATIENTS WITH DISTANT SOFT TISSUE METASTASIS OF CARCINOMA
Naohisa Miyakoshi
Favorite
(
P 285
)
IMPACT OF ACRIDINE ORANGE IN PATIENTS WITH LOCAL RECURRENT SOFT TISSUE SARCOMA
Naohisa Miyakoshi
Favorite
Mizoguchi, Chiharu
Department of Medical Oncology, National Cancer Center Hospital
(
P 147
)
ANALYSIS OF INFLAMMATORY BIOMARKERS AS PREDICTORS OF TREATMENT EFFICACY IN SOFT TISSUE SARCOMA TREATED WITH TRABECTEDIN
Chiharu Mizoguchi
Favorite
Mizushima, Emi
Sapporo Medical University School of Medicine
(
P 084
)
PROGNOSTIC FACTORS IN PATIENTS WITH DISTANT SOFT TISSUE METASTASIS OF CARCINOMA
Emi Mizushima
Favorite
(
P 285
)
IMPACT OF ACRIDINE ORANGE IN PATIENTS WITH LOCAL RECURRENT SOFT TISSUE SARCOMA
Emi Mizushima
Favorite
Moding, Everett
Stanford University
(
P 130
)
MONITORING SOFT TISSUE SARCOMA RESPONSE TO IMMUNE CHECKPOINT INHIBITION AND CRYOTHERAPY WITH CIRCULATING TUMOR DNA ANALYSIS
Everett Moding
Favorite
Mogal, Harveshp
University of Washington/Fred Hutch Cancer Center
(
P 063
)
A RETROSPECTIVE COHORT ANALYSIS EVALUATING THE NATURAL HISTORY AND CHARACTERISTICS OF ANGIOSARCOMAS OF THE BREAST
Harveshp Mogal
Favorite
mohamed, mohamed
Ain Shams university
(
P 067
)
CLINICAL-EPIDEMIOLOGICAL AND TREATMENT FACTORS IMPACT ON SURVIVAL IN EGYPTIAN PATIENTS WITH HEAD AND NECK SARCOMA: A RETROSPECTIVE CASE-SERIES ANALYSIS
mohamed mohamed
Favorite
Mohammed, Kabir
The Royal Marsden NHS Foundation Trust
(
P 152
)
FINAL RESULTS OF GEMMK: A PHASE I TRIAL OF GEMCITABINE AND PEMBROLIZUMAB IN PATIENTS WITH LEIOMYOSARCOMA AND UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Kabir Mohammed
Favorite
Molea, Francesca
Radiology Service, CTO Hospital, AOU Città della Salute e della Scienza di Torino
(
P 058
)
SARCOPENIA AS A NEGATIVE PROGNOSTIC FACTOR IN LOCALIZED EXTREMITIES/TRUNK WALL SOFT TISSUE SARCOMAS
Francesca Molea
Favorite
Mondaza, Jose Lucinio
HG Villalba and Instituto de Investigaciones Sanitarias Fundación Jimenez Diaz
(
P 135
)
PREDICTIVE VALUE OF ISG15 AND PPAP2B IN SOLITARY FIBROUS TUMOR TREATED WITH SUNITINIB AND NIVOLUMAB: A CORRELATIVE STUDY FROM IMMUNOSARC, A SPANISH GROUP FOR RESEARCH ON SARCOMA (GEIS) PHASE II TRIAL
Jose Lucinio Mondaza
Favorite
Monga, Varun
University of Iowa Hospitals and Clinics
(
P 159
)
NEOADJUVANT INTRATUMORAL HIGH DOSE TALIMOGENE LAHERPAREPVEC (TVEC) WITH CONCURRENT RADIATION IN HIGH-RISK EXTREMITY AND TRUNK SOFT-TISSUE SARCOMAS
Varun Monga
Favorite
(
P 160
)
NEOADJUVANT PHARMACOLOGICAL ASCORBATE WITH CONCURRENT RADIATION IN LOCALLY ADVANCED SOFT-TISSUE SARCOMA OF EXTREMITY/TRUNK AND RETROPERITONEUM
Varun Monga
Favorite
(
P 312
)
A PHASE 1/2 STUDY OF CFT8634, A NOVEL BIFUNCTIONAL DEGRADATION ACTIVATING COMPOUND (BIDAC) DEGRADER OF BRD9, IN SYNOVIAL SARCOMA AND SMARCB1-NULL TUMORS
Varun Monga
Favorite
Montoya, Denisse
The Life Raft Group
(
P 110
)
PHASE I RESULTS FROM A MULTI-PHASE COMPREHENSIVE GENOMIC SEQUENCING TUMOR STUDY IN GASTROINTESTINAL STROMAL TUMOR PATIENTS
Denisse Montoya
Favorite
Monument, Michael
University of Calgary McCaig Bone and Joint Institute
(
P 128
)
INVESTIGATING THE ROLE OF MACROPHAGES IN A MURINE MODEL OF SOFT TISSUE SARCOMA
Michael Monument
Favorite
(
P 142
)
USE OF SMALL MOLECULE STIMULATE OF TYPE-1 INTERFERON GENES (STING) AGONIST IMMUNOTHERAPY FOR CANINE SARCOMA: A CROSS-SPECIES ANALYSIS
Michael Monument
Favorite
(
P 205
)
PREOPERATIVE CHEMORADIATION (MODIFIED EILBER PROTOCOL) VERSUS NEOADJUVANT/ ADJUVANT RADIOTHERAPY FOR SOFT TISSUE EXTREMITY SARCOMAS: A POPULATION BASED ANALYSIS IN ALBERTA
Michael Monument
Favorite
(
P 286
)
INDICATIONS AND LONGEVITY OF ENDOPROSTHETIC RECONSTRUCTIONS FOR PATIENTS WITH METASTATIC BONE DISEASE
Michael Monument
Favorite
Mooney, Srikanth
Tata Memorial Centre
(
P 03
)
DEMOGRAPHICS, PRACTICE PATTERNS, CHALLENGES AND OUTCOMES OF SYNOVIAL SARCOMA PATIENTS FROM A TERTIARY CARE CENTRE FROM A LARGE LOW-MIDDLE INCOME COUNTRY
Srikanth Mooney
Favorite
(
P 09
)
OUTCOMES, PROGNOSTIC FACTORS AND TREATMENT COMPLIANCE IN OSTEOSARCOMA CASES TREATED WITH AN INDIGENOUS, LOW-COST PROTOCOL, OGS-12, IN A TERTIARY CARE CANCER CENTRE IN INDIA
Srikanth Mooney
Favorite
Moradhkani, Ania
Sarcoma Oncology Research Center
(
P 137
)
SAINT: FIVE YEAR RESULTS OF A PHASE 2 TRIAL USING IPILIMUMAB (I), NIVOLUMAB (N) AND TRABECTEDIN (T) FOR PREVIOUSLY UNTREATED ADVANCED SOFT TISSUE SARCOMA [NCT03138161]
Ania Moradhkani
Favorite
Moradkhani, Ania
Sarcoma Oncology Center
(
P 122
)
AN UPDATE ON TNT: A PHASE-2 STUDY OF THE EFFICACY AND SAFETY OF TALIMOGENE LAHERPAREPVEC, NIVOLUMAB, AND TRABECTEDIN IN ADVANCED SARCOMA
Ania Moradkhani
Favorite
(
P 126
)
GALLANT: A PHASE 2 STUDY USING METRONOMIC GEMCITABINE, DOXORUBICIN, NIVOLUMAB, AND DOCETAXEL AS SECOND/THIRD-LINE THERAPY FOR ADVANCED SARCOMA (NCT04535713)
Ania Moradkhani
Favorite
(
P 132
)
PHASE 1/2 COMBINATION REGIMEN WITH IPILIMUMAB (I), NIVOLUMAB (N), AND TRABECTEDIN (T) AS FIRST-LINE THERAPY FOR ADVANCED LEIOMYOSARCOMA [NCT03138161]
Ania Moradkhani
Favorite
Morales, Rafael
Hospital universitario son espases
(
P 119
)
SURGICAL MANAGEMENT OF GASTROINTESTINAL STROMAL TUMOURS SARCOMATOSIS (GISTOSIS). A RETROSPECTIVE MULTI-INSTITUTIONAL STUDY
Rafael Morales
Favorite
Moran, Steven
Mayo Clinic
(
P 291
)
OUTCOME OF MULTIDISCIPLINARY TREATMENT OF MERKEL CELL CARCINOMA OF THE UPPER EXTREMITY
Steven Moran
Favorite
(
P 293
)
OUTCOMES OF MULTIDISCIPLINARY TREATMENT OF MERKEL CELL CARCINOMA OF THE LOWER EXTREMITY
Steven Moran
Favorite
(
P 296
)
PET IMAGING VERSUS CLINICAL EXAMINATION IN DETERMINING LYMPH NODE INVOLVEMENT IN MERKEL CELL CARCINOMA OF THE EXTREMITY
Steven Moran
Favorite
Mordstein, Volker
Paracelsus Medical University
(
P 231
)
COMPREHENSIVE MOLECULAR PROFILING OF FOLLICULAR DENDRITIC CELL SARCOMA
Volker Mordstein
Favorite
Moreno, Victor
START MADRID-FJD, Hospital Universitario Fundación Jiménez Díaz
(
P 107
)
LONG-TERM EFFICACY AND SAFETY OF LAROTRECTINIB IN ADULT PATIENTS WITH TRK FUSION SARCOMAS
Victor Moreno
Favorite
(
P 127
)
IDENTIFYING MAGE-A4-POSITIVE TUMORS FOR SPEAR T-CELL THERAPIES IN HLA-A*02-ELIGIBLE PATIENTS
Victor Moreno
Favorite
Morgan, Jeffrey
Dana-Farber Cancer Institute
(
P 099
)
CONCURRENT INHIBITION OF CDK2 ADDS TO THE ANTI-TUMOR ACTIVITY OF CDK4/6 INHIBITION IN GIST
Jeffrey Morgan
Favorite
Morgenstern, Daniel
Hospital for Sick Children and University of Toronto
(
P 043
)
A MULTICENTER, OPEN-LABEL, RANDOMIZED, PHASE 2 STUDY OF LENVATINIB IN COMBINATION WITH IFOSFAMIDE AND ETOPOSIDE VERSUS IFOSFAMIDE AND ETOPOSIDE IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS WITH RELAPSED OR REFRACTORY OSTEOSARCOMA
Daniel Morgenstern
Favorite
(
P 131
)
MUCIN 16 (CANCER ANTIGEN 125) EXPRESSION IN EPITHELIOID SARCOMA LEADS TO SINGLE-PATIENT STUDY WITH BISPECIFIC T-CELL ENGAGER UBAMATAMAB (MUCIN16-CD3): A BENCH-TO-BEDSIDE EXPERIENCE
Daniel Morgenstern
Favorite
Morilla, Joseph
The Royal Marsden Hospital
(
P 085
)
RADIATION ASSOCIATED ANGIOSARCOMAS OF THE BREAST: MULTIFOCALITY WARRANTS AGGRESSIVE ONCOLOGICAL STRATEGY
Joseph Morilla
Favorite
Mori, Shiori
Nara Medical University
(
P 181
)
MITOCHONDRIAL TRANSFER FROM MESENCHYMAL STEM CELSS MEDIATED BY HMGB1 COULD BE INVOLVED IN DRUG RESISTANCE IN OSTEOSARCOMA CELLS.
Shiori Mori
Favorite
Morosi, Carlo
Fondazione IRCCS Istituto Nazionale dei Tumori
(
P 016
)
ACTIVITY OF CHEMOTHERAPY IN MESENCHYMAL CHONDROSARCOMA: A MULTICENTRE RETROSPECTIVE ANALYSIS WITHIN THE ITALIAN SARCOMA GROUP
Carlo Morosi
Favorite
(
P 145
)
A RETROSPECTIVE CASE SERIES ANALYSIS OF 22 RHABDOMYOSARCOMA PATIENTS WITH SPINDLE-CELL/SCLEROSING MORPHOLOGY
Carlo Morosi
Favorite
(
P 225
)
TRABECTEDIN WITH CONCOMITANT RADIATION THERAPY FOR PATIENTS WITH RESECTABLE RETROPERITONEAL LIPOSARCOMA OR LEIOMYOSARCOMA: A PHASE I/II TRIAL OF SPANISH (GEIS), ITALIAN (ISG) AND FRENCH (FSG) GROUPS
Carlo Morosi
Favorite
(
P 292
)
OUTCOMES IN PLEOMORPHIC LIPOSARCOMA OF THE EXTREMITY AND TRUNK: IS MULTIMODALITY THERAPY INDICATED?
Carlo Morosi
Favorite
Mortensen, Helene
Department of Oncology, Copenhagen University Hospital, Herlev and Gentofte Hospital
(
P 120
)
THE DIAGNOSTIC AND PROGNOSTIC VALUE OF PLASMA SMALL EXTRACELLULAR VESICLES PHENOTYPE IN PATIENTS WITH GASTROINTESTINAL STROMAL TUMOUR
Helene Mortensen
Favorite
Mosha, Maua
Johns Hopkins All Children's Hospital
(
P 305
)
THE INCIDENCE OF THROMBOEMBOLIC EVENTS DURING HOSPITALIZATIONS FOLLOWING SURGICAL RESECTION OF LOWER EXTREMITY SARCOMAS IN CHILDREN: UTILIZING THE PEDIATRIC HEALTH INFORMATION SYSTEM (PHIS) DATABASE
Maua Mosha
Favorite
Mosley, Amber
Indiana University
(
P 192
)
TARGETING PI3K/MTOR MITIGATES RESISTANCE TO CDK4/6 INHIBITION IN RB-PROFICIENT PEDIATRIC AND AYA OSTEOSARCOMAS
Amber Mosley
Favorite
Mosseri, Veronique
Institut Curie
(
P 026
)
IS THERE STILL A PLACE FOR BONE MARROW SAMPLING IN VERY HIGH RISK EWING SARCOMA? ROLE OF FDG PET/CT IN THE INITIAL STAGING OF VERY HIGH RISK EWING SARCOMA IN A PROSPECTIVE PHASE II MULTICENTRIC STUDY.
Veronique Mosseri
Favorite
Mostert, Cassidy
Leiden University Medical center
(
P 051
)
NON-INVASIVE DETECTION OF SOFT TISSUE SARCOMA USING VOLATILE ORGANIC COMPOUNDS IN EXHALED BREATH: A PILOT STUDY
Cassidy Mostert
Favorite
Mottard, Sophie
CIUSSS de l'ESt-de-l'Île-de-Montreal
(
P 054
)
PROGNOSTIC FACTORS AFFECTING SURVIVAL OF PATIENTS WITH PRIMARY MUSCULOSKELETAL SARCOMAS FOLLOWING PULMONARY METASTASECTOMY
Sophie Mottard
Favorite
(
P 308
)
REFERRAL DELAYS OF QUEBEC SARCOMA POPULATION : A PROSPECTIVE COHORT STUDY
Sophie Mottard
Favorite
Mott, Sarah
Holden Comprehensive Cancer Center
(
P 160
)
NEOADJUVANT PHARMACOLOGICAL ASCORBATE WITH CONCURRENT RADIATION IN LOCALLY ADVANCED SOFT-TISSUE SARCOMA OF EXTREMITY/TRUNK AND RETROPERITONEUM
Sarah Mott
Favorite
Moura, David
HG Villalba and Instituto de Investigaciones Sanitarias Fundación Jimenez Diaz
(
P 113
)
PROGNOSTIC AND/OR PREDICTIVE VALUE OF EXON 11 MUTATIONS IN TUMOR RESPONSE TO IMATINIB IN METASTATIC GASTROINTESTINAL STROMAL TUMOR :RETROSPECTIVE ANALYSIS OF A MULTICENTRIC NATIONAL REGISTRY
David Moura
Favorite
(
P 135
)
PREDICTIVE VALUE OF ISG15 AND PPAP2B IN SOLITARY FIBROUS TUMOR TREATED WITH SUNITINIB AND NIVOLUMAB: A CORRELATIVE STUDY FROM IMMUNOSARC, A SPANISH GROUP FOR RESEARCH ON SARCOMA (GEIS) PHASE II TRIAL
David Moura
Favorite
(
P 161
)
PALBOSARC: A PHASE II TRIAL OF PALBOCICLIB IN ADVANCED SARCOMA OVEREXPRESSING CDK4 GENE EXCLUDING DEDIFFERENTIATED LIPOSARCOMA (DD LPS): A STUDY FROM THE SPANISH GROUP FOR RESEARCH ON SARCOMA (GEIS).
David Moura
Favorite
Movva, Sujana
Memorial Sloan Kettering Cancer Center
(
P 134
)
PHASE II STUDY OF RUCAPARIB AND NIVOLUMAB IN PATIENTS WITH LEIOMYOSARCOMA
Sujana Movva
Favorite
(
P 143
)
A PHASE 1 B LEAD-IN TO A RANDOMIZED PHASE 2 TRIAL OF LURBINECTEDIN PLUS DOXORUBICIN IN LEIOMYOSARCOMA (LMS): RESULTS FROM THE PHASE 1B SOFT-TISSUE SARCOMA (STS) LEAD-IN
Sujana Movva
Favorite
Moyers, Justin
University of California, Irvine
(
P 269
)
LANDSCAPE OF GENOMIC ALTERATIONS IN 115 PATIENTS WITH DESMOID FIBROMATOSIS IN THE AACR GENIE REAL WORLD DATABASE: CLINICAL IMPLICATIONS
Justin Moyers
Favorite
Moynihan, Kevin
Cogent Biosciences
(
P 320
)
PEAK STUDY: A PHASE 3 RANDOMIZED, OPEN-LABEL, MULTICENTER CLINICAL STUDY OF BEZUCLASTINIB (CGT9486) AND SUNITINIB VERSUS SUNITINIB IN PATIENTS WITH GASTROINTESTINAL STROMAL TUMORS
Kevin Moynihan
Favorite
Muñoz, Cristobal
Hospital virgen del rocio
(
P 119
)
SURGICAL MANAGEMENT OF GASTROINTESTINAL STROMAL TUMOURS SARCOMATOSIS (GISTOSIS). A RETROSPECTIVE MULTI-INSTITUTIONAL STUDY
Cristobal Muñoz
Favorite
(
P 225
)
TRABECTEDIN WITH CONCOMITANT RADIATION THERAPY FOR PATIENTS WITH RESECTABLE RETROPERITONEAL LIPOSARCOMA OR LEIOMYOSARCOMA: A PHASE I/II TRIAL OF SPANISH (GEIS), ITALIAN (ISG) AND FRENCH (FSG) GROUPS
Cristobal Muñoz
Favorite
Mucci, Lorenzo Ramos
University of Oxford
(
P 252
)
THE GENOMIC LANDSCAPE OF CLEAR CELL SARCOMA RESEARCH INITIATIVE
Lorenzo Ramos Mucci
Favorite
Mukherjee, Elina
Department of Pediatrics, University of Pittsburgh
(
P 036
)
STAG2 LOSS ENCHANCES SENSITIVITY TO DNA DAMAGE YET REDUCES DNA DAMAGE-INDUCED INFLAMMATION IN EWING SARCOMA
Elina Mukherjee
Favorite
Munoz, Maria
University of California Davis
(
P 251
)
TARGETING SOFT TISSUE SARCOMA CANCER STEM CELLS IMPROVES DOXORUBICIN SENSITIVITY IN VITRO
Maria Munoz
Favorite
Murahashi, Yasutaka
Sapporo Medical University School of Medicine
(
P 084
)
PROGNOSTIC FACTORS IN PATIENTS WITH DISTANT SOFT TISSUE METASTASIS OF CARCINOMA
Yasutaka Murahashi
Favorite
(
P 285
)
IMPACT OF ACRIDINE ORANGE IN PATIENTS WITH LOCAL RECURRENT SOFT TISSUE SARCOMA
Yasutaka Murahashi
Favorite
Murakami, Hideki
Department of Orthopaedic Surgery, Nagoya City University
(
P 150
)
CLINICAL CHARACTERISTICS OF PRIMARY CUTANEOUS AND SUBCUTANEOUS EWING SARCOMA FAMILY OF TUMORS
Hideki Murakami
Favorite
Muraleedharan, Ranjith
Center for Development of Therapeutics, Broad Institute of MIT & Harvard, Cambridge, MA
(
P 178
)
HIGH FREQUENCY OF NAPRT-SILENCING IN NEUROBLASTOMA AND RHABDOMYSARCOMA CONFERS SENSITIVITY TO TARGETING OF NAD+ METABOLISM USING NAMPT INHIBITORS
Ranjith Muraleedharan
Favorite
Murphy, Erin
Cleveland Clinic
(
P 310
)
TUMOR REVIEW BOARD FOR OSTEOSARCOMA (TURBO): BIMONTHLY, MULTI-INSTITUTIONAL, MULTIDISCIPLINARY VIRTUAL TUMOR BOARD FOR OSTEOSARCOMA
Erin Murphy
Favorite
(
P 311
)
VIRTUAL VISITS FOR SARCOMAS AND OTHER RARE CANCERS INCLUDING DESMOIDS: THE EVOLUTION OF INFORMATION AND EDUCATIONAL OPPORTUNITIES TO IMPOVE HEALTH: 2017-2022
Erin Murphy
Favorite
Murtas, Fabio
Veneto Institute of Oncology IOV – IRCCS
(
P 06
)
GONADOTOXICITY RISK EVALUATION AND REPRODUCTIVE OUTCOMES IN YOUNG ADULTS WITH SOFT TISSUE AND BONE SARCOMA TREATED WITH CHEMOTHERAPY AND/OR RADIATION THERAPY: A SINGLE CENTER RETROSPECTIVE STUDY
Fabio Murtas
Favorite
Muscal, Jodi
Pfizer Inc
(
P 323
)
PHASE 2 STUDY TO EVALUATE PALBOCICLIB (IBRANCE®) IN COMBINATION WITH IRINOTECAN AND TEMOZOLOMIDE IN PEDIATRIC PATIENTS WITH RECURRENT OR REFRACTORY EWING SARCOMA.
Jodi Muscal
Favorite
Mussi, Chiara E.
Bayer HealthCare Pharmaceuticals
(
P 107
)
LONG-TERM EFFICACY AND SAFETY OF LAROTRECTINIB IN ADULT PATIENTS WITH TRK FUSION SARCOMAS
Chiara E. Mussi
Favorite
Myhre, Sue Lynn
Institute for Limb Preservation, Presbyterian/St. Luke’s Medical Center
(
P 294
)
PERCUTANEOUS STABILIZATION OF PATHOLOGIC FRACTURES OF THE PELVIS AND SACRUM
Sue Lynn Myhre
Favorite
Myron, Mark
The University of Kansas Health System
(
P 028
)
LONG TERM SURVIVAL OF AN ANTERIOR SKULL BASE OSTEOSARCOMA ARISING FROM FIBROUS DYSPLASIA TREATED WITH TRIMODALITY THERAPY
Mark Myron
Favorite
Back to Top
